X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-05-17 | XFOR | Baldry Mark | Chief Commercial Officer | P - Purchase | $0.55 | +35,050 | 729,173 | +5% | +$19,252 | |||||
2025-01-24 | XFOR | Ragan Paula | Pres, CEO | S - Sale | $0.45 | -76,473 | 1,087,386 | -7% | -$34,719 | ||||||
2025-01-24 | XFOR | Mostafa Adam S. | CFO | S - Sale | $0.45 | -74,773 | 0 | -100% | -$33,947 | ||||||
2025-01-24 | XFOR | Baldry Mark | Chief Commercial Officer | S - Sale | $0.45 | -29,159 | 94,123 | -24% | -$13,241 | ||||||
2025-01-24 | XFOR | Dibiase Mary | COO | S - Sale | $0.45 | -22,258 | 490,980 | -4% | -$10,094 | ||||||
2025-01-24 | XFOR | Arbet-Engels Christophe | Chief Medical Officer | S - Sale | $0.45 | -11,624 | 14,207 | -45% | -$5,284 | ||||||
2024-11-15 | XFOR | Ragan Paula | Pres, CEO | S - Sale | $0.39 | -31,897 | 993,919 | -3% | -$12,583 | ||||||
2024-10-15 | XFOR | Ragan Paula | Pres, CEO | S - Sale | $0.56 | -31,897 | 1,025,816 | -3% | -$17,926 | ||||||
2024-10-07 | XFOR | Mostafa Adam S. | CFO | S - Sale | $0.55 | -230,645 | 0 | -100% | -$126,901 | ||||||
2024-10-07 | XFOR | Baldry Mark | Chief Commercial Officer | S - Sale | $0.58 | -11,127 | 48,509 | -19% | -$6,506 | ||||||
2024-10-07 | XFOR | Ragan Paula | Pres, CEO | S - Sale | $0.55 | -239,436 | 1,057,713 | -18% | -$131,522 | ||||||
2024-10-07 | XFOR | Dibiase Mary | COO | S - Sale | $0.57 | -67,695 | 452,060 | -13% | -$38,329 | ||||||
2024-10-07 | XFOR | Taveras Arthur | Chief Scientific Officer | S - Sale | $0.56 | -76,920 | 388,026 | -17% | -$43,306 | ||||||
2024-09-09 | XFOR | Dibiase Mary | COO | S - Sale | $0.66 | -2,642 | 289,110 | -1% | -$1,738 | ||||||
2024-03-11 | XFOR | Taveras Arthur | Chief Scientific Officer | S - Sale | $0.88 | -14,235 | 234,301 | -6% | -$12,552 | ||||||
2024-03-11 | XFOR | Ragan Paula | Pres, CEO | S - Sale | $0.88 | -49,678 | 765,068 | -6% | -$43,856 | ||||||
2024-03-11 | XFOR | Mostafa Adam S. | CFO | S - Sale | $0.88 | -52,500 | 0 | -100% | -$46,347 | ||||||
2024-03-11 | XFOR | Dibiase Mary | COO | S - Sale | $0.88 | -15,409 | 291,752 | -5% | -$13,591 | ||||||
2024-02-12 | XFOR | Dibiase Mary | COO | S - Sale | $1.01 | -3,683 | 307,161 | -1% | -$3,709 | ||||||
2024-02-12 | XFOR | Taveras Arthur | Chief Scientific Officer | S - Sale | $1.01 | -787 | 248,536 | 0% | -$793 | ||||||
2024-02-12 | XFOR | Ragan Paula | Pres, CEO | S - Sale | $1.01 | -21,695 | 814,746 | -3% | -$21,892 | ||||||
2024-02-12 | XFOR | Mostafa Adam S. | CFO | S - Sale | $1.01 | -27,721 | 52,500 | -35% | -$27,973 | ||||||
| M | 2023-11-01 | XFOR | Ragan Paula | Pres, CEO | S - Sale | $0.76 | -239,437 | 836,441 | -22% | -$181,573 | |||||
2023-11-01 | XFOR | Mostafa Adam S. | CFO | S - Sale | $0.73 | -230,645 | 80,221 | -74% | -$168,371 | ||||||
2023-11-01 | XFOR | Dibiase Mary | COO | S - Sale | $0.73 | -67,695 | 310,844 | -18% | -$49,417 | ||||||
2023-11-01 | XFOR | Baldry Mark | Chief Commercial Officer | S - Sale | $0.73 | -10,257 | 24,690 | -29% | -$7,488 | ||||||
2023-11-01 | XFOR | Taveras Arthur | Chief Scientific Officer | S - Sale | $0.73 | -67,695 | 249,323 | -21% | -$49,417 | ||||||
2023-09-08 | XFOR | Dibiase Mary | COO | S - Sale | $1.25 | -2,642 | 147,894 | -2% | -$3,300 | ||||||
2023-08-18 | XFOR | Wyzga Michael S | Dir | P - Purchase | $1.20 | +25,000 | 76,667 | +48% | +$29,875 | ||||||
2023-08-10 | XFOR | Stewart Murray | Interim Chief Medical Officer | S - Sale | $1.06 | -130,056 | 146,504 | -47% | -$137,859 | ||||||
2023-06-30 | XFOR | Dibiase Mary | COO | S - Sale | $1.89 | -464 | 150,536 | 0% | -$877 | ||||||
2023-06-30 | XFOR | Mostafa Adam S. | CFO | S - Sale | $1.89 | -2,641 | 80,221 | -3% | -$4,991 | ||||||
2023-06-23 | XFOR | Dibiase Mary | COO | S - Sale | $1.93 | -857 | 151,000 | -1% | -$1,654 | ||||||
2023-06-23 | XFOR | Mostafa Adam S. | CFO | S - Sale | $1.93 | -5,417 | 82,862 | -6% | -$10,455 | ||||||
2023-06-23 | XFOR | Ragan Paula | Pres, CEO | S - Sale | $1.92 | -6,724 | 543,797 | -1% | -$12,910 | ||||||
2023-06-15 | XFOR | Dibiase Mary | COO | S - Sale | $2.23 | -857 | 151,857 | -1% | -$1,911 | ||||||
2023-06-15 | XFOR | Mostafa Adam S. | CFO | S - Sale | $2.22 | -5,417 | 88,279 | -6% | -$12,026 | ||||||
2023-06-15 | XFOR | Ragan Paula | Pres, CEO | S - Sale | $2.23 | -6,724 | 550,521 | -1% | -$14,995 | ||||||
2023-05-31 | XFOR | Ragan Paula | Pres, CEO | S - Sale | $1.95 | -6,292 | 557,245 | -1% | -$12,269 | ||||||
2023-03-10 | XFOR | Dibiase Mary | COO | S - Sale | $0.84 | -18,192 | 152,714 | -11% | -$15,281 | ||||||
2023-03-10 | XFOR | Mostafa Adam S. | CFO | S - Sale | $0.84 | -52,500 | 93,696 | -36% | -$44,100 | ||||||
2023-03-10 | XFOR | Taveras Arthur | Chief Scientific Officer | S - Sale | $0.84 | -16,806 | 86,373 | -16% | -$14,117 | ||||||
2023-03-10 | XFOR | Ragan Paula | Pres, CEO | S - Sale | $0.84 | -49,678 | 563,537 | -8% | -$41,730 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |